Fibrinolysis and the control of blood coagulation

Blood Reviews

Volumn 29, Issue 1, 2015, Pages 17-24

  Chapin, John C ^a   Hajjar, Katherine A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coagulation; Fibrin(ogen); Fibrinolysis; Hemostasis; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; LIPOCORTIN 2; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN C; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; FIBRINOGEN VARIANT;

AFIBRINOGENEMIA; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; DYSFIBRINOGENEMIA; ELASTOGRAPHY; EUGLOBULIN LYSIS TEST; FIBRIN DEPOSITION; FIBRIN FORMATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEMOPHILIA; HEMOSTASIS; HUMAN; HYPOTHYROIDISM; IMMUNOMODULATION; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; NONHUMAN; PROMYELOCYTIC LEUKEMIA; REVIEW; THROMBOELASTOMETRY; THROMBOSIS; ANIMAL; BLOOD; BLOOD COAGULATION DISORDERS, INHERITED; GENETICS; HEMOPHILIA A; METABOLISM; PHYSIOLOGY; THROMBOELASTOGRAPHY;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS, INHERITED; FIBRIN; FIBRIN CLOT LYSIS TIME; FIBRINOGENS, ABNORMAL; FIBRINOLYSIS; HEMOPHILIA A; HEMOSTASIS; HUMANS; THROMBELASTOGRAPHY;

EID: 84922002483     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.09.003     Document Type: Article

References (161)

1. Broos K., Feys H.B., De Meyer S.F., Vanhoorelbeke K., Deckmyn H. Platelets at work in primary hemostasis. Blood Rev 2011, 25(4):155-167.
2. de Witt S.M., Verdoold R., Cosemans J.M., Heemskerk J.W. Insights into platelet-based control of coagulation. Thromb Res 2014, 133(Suppl. 2):S139-S148.
3. Furie B. Pathogenesis of thrombosis. Hematology Am Soc Hematol Educ Program 2009, 255-258.
4. Bagoly Z., Koncz Z., Hársfalvi J., Muszbek L. Factor XIII, clot structure, thrombosis. Thromb Res 2012, 129(3):382-387.
5. Hajjar K.A. The molecular basis of fibrinolysis. Nathan and Orkin's Hematology of Infancy and Childhood 2014, Saunders/Elsevier, Philadelphia. 8th ed. S.A. Orkin, D.G. Nathan, D. Ginsburg, A.T. Look, D.E. Fisher, S.E. Lux (Eds.).
6. Wolberg A.S. Thrombin generation and fibrin clot structure. Blood Rev 2007, 21(3):131-142.
7. Aleman M.M., Walton B.L., Byrnes J.R., Wolberg A.S. Fibrinogen and red blood cells in venous thrombosis. Thromb Res 2014, 133(Suppl. 1):S38-S40.
8. Gersh K.C., Edmondson K.E., Weisel J.W. Flow rate and fibrin fiber alignment. J Thromb Haemost 2010, 8(12):2826-2828.
9. Campbell R.A., Aleman M., Gray L.D., Falvo M.R., Wolberg A.S. Flow profoundly influences fibrin network structure: implications for fibrin formation and clot stability in haemostasis. Thromb Haemost 2010, 104(6):1281-1284.
10. Neeves K.B., Illing D.A., Diamond S.L. Thrombin flux and wall shear rate regulate fibrin fiber deposition state during polymerization under flow. Biophys J 2010, 98(7):1344-1352.
11. Blombäck B., Carlsson K., Fatah K., Hessel B., Procyk R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994, 75(5):521-538.
12. Wolberg A.S., Gabriel D.A., Hoffman M. Analyzing fibrin clot structure using a microplate reader. Blood Coagul Fibrinolysis 2002, 13(6):533-539.
13. Wolberg A.S., Monroe D.M., Roberts H.R., Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. Blood 2003, 101(8):3008-3013.
14. Undas A., Ariëns R.A. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011, 31(12):e88-e99.
15. Cilia La Corte A.L., Philippou H., Ariëns R.A. Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chem Struct Biol 2011, 83:75-127.
16. Ariëns R.A. Fibrin(ogen) and thrombotic disease. J Thromb Haemost 2013, 11(Suppl. 1):294-305.
17. Wolberg A.S., Allen G.A., Monroe D.M., Hedner U., Roberts H.R., Hoffman M. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005, 131(5):645-655.
18. Gray L.D., Hussey M.A., Larson B.M., Machlus K.R., Campbell R.A., Koch G., et al. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma. Thromb Res 2011, 128(6):570-576.
19. Cawthern K.M., van 't Veer C., Lock J.B., DiLorenzo M.E., Branda R.F., Mann K.G. Blood coagulation in hemophilia A and hemophilia C. Blood 1998, 91(12):4581-4592.
20. Carr M.E., Alving B.M. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coagul Fibrinolysis 1995, 6(6):567-573.
21. Gabriel D.A., Muga K., Boothroyd E.M. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992, 267(34):24259-24263.
22. Longstaff C., Thelwell C., Williams S.C., Silva M.M., Szabó L., Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011, 117(2):661-668.
23. Collet J.P., Lesty C., Montalescot G., Weisel J.W. Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots. J Biol Chem 2003, 278(24):21331-21335.
24. Cooper A.V., Standeven K.F., Ariëns R.A. Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure. Blood 2003, 102(2):535-540.
25. Mannila M.N., Lovely R.S., Kazmierczak S.C., Eriksson P., Samnegård A., Farrell D.H., et al. Elevated plasma fibrinogen gamma' concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007, 5(4):766-773.
26. Walton B.L., Getz T.M., Bergmeier W., Lin F.C., Uitte de Willige S., Wolberg A.S. The fibrinogen γA/γ' isoform does not promote acute arterial thrombosis in mice. J Thromb Haemost 2014, 12(5):680-689.
27. Rijken D.C., Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009, 7(1):4-13.
28. Bu G., Warshawsky I., Schwartz A.L. Cellular receptors for the plasminogen activators. Blood 1994, 83(12):3427-3436.
29. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. Br J Haematol 2005, 129(3):307-321.
30. Hoylaerts M., Rijken D.C., Lijnen H.R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982, 257(6):2912-2919.
31. Tate K.M., Higgins D.L., Holmes W.E., Winkler M.E., Heyneker H.L., Vehar G.A. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987, 26(2):338-343.
32. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu Rev Biochem 1983, 52:655-709.
33. Schneider M., Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004, 279(14):13333-13339.
34. Sprengers E.D., Kluft C. Plasminogen activator inhibitors. Blood 1987, 69(2):381-387.
35. Coolman M., de Groot C.J., Steegers E.A., Geurts-Moespot A., Thomas C.M., Steegers-Theunissen R.P., et al. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. Eur J Obstet Gynecol Reprod Biol 2006, 128(1-2):22-28.
36. Coolman M., Timmermans S., de Groot C.J., Russcher H., Lindemans J., Hofman A., et al. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes. Obstet Gynecol 2012, 119(6):1190-1200.
37. Broze G.J., Higuchi D.A. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood 1996, 88(10):3815-3823.
38. Mosnier L.O., Lisman T., van den Berg H.M., Nieuwenhuis H.K., Meijers J.C., Bouma B.N. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001, 86(4):1035-1039.
39. Plow E.F., Collen D. The presence and release of alpha 2-antiplasmin from human platelets. Blood 1981, 58(6):1069-1074.
40. Ichinose A., Tamaki T., Aoki N. Factor XIII-mediated cross-linking of NH2-terminal peptide of alpha 2-plasmin inhibitor to fibrin. FEBS Lett 1983, 153(2):369-371.
41. Kimura S., Aoki N. Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor. J Biol Chem 1986, 261(33):15591-15595.
42. Doolittle R.F. Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis. Cardiovasc Hematol Agents Med Chem 2008, 6(3):181-189.
43. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci 1992, 667:52-63.
44. Bai H., Baik N., Kiosses W.B., Krajewski S., Miles L.A., Parmer R.J. The novel plasminogen receptor, plasminogen receptor(KT) (Plg-R(KT)), regulates catecholamine release. J Biol Chem 2011, 286(38):33125-33133.
45. Stahl A., Mueller B.M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995, 129(2):335-344.
46. Okamoto T., Schlegel A., Scherer P.E., Lisanti M.P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998, 273(10):5419-5422.
47. Rescher U., Gerke V. S100A10/p11: family, friends and functions. Pflugers Arch 2008, 455(4):575-582.
48. Gerke V., Creutz C.E., Moss S.E. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 2005, 6(6):449-461.
49. Fatimathas L., Moss S.E. Annexins as disease modifiers. Histol Histopathol 2010, 25(4):527-532.
50. Rescher U., Gerke V. Annexins-unique membrane binding proteins with diverse functions. J Cell Sci 2004, 117(Pt 13):2631-2639.
51. Hajjar K.A., Hamel N.M. Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase. J Biol Chem 1990, 265(5):2908-2916.
52. Waisman D.M. Annexin II, tetramer: structure and function. Mol Cell Biochem 1995, 149-150:301-322.
53. Flood E.C., Hajjar K.A. The annexin A2 system and vascular homeostasis. Vascul Pharmacol 2011, 54(3-6):59-67.
54. Cesarman-Maus G., Cantú-Brito C., Barinagarrementeria F., Villa R., Reyes E., Sanchez-Guerrero J., et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in cerebral venous thrombosis. Stroke 2011, 42(2):501-503.
55. Cesarman-Maus G., Ríos-Luna N.P., Deora A.B., Huang B., Villa R., Cravioto Mdel C., et al. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 2006, 107(11):4375-4382.
56. Sebastiani P., Ramoni M.F., Nolan V., Baldwin C.T., Steinberg M.H. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005, 37(4):435-440.
57. Flanagan J.M., Frohlich D.M., Howard T.A., Schultz W.H., Driscoll C., Nagasubramanian R., et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011, 117(24):6681-6684.
58. Menell J.S., Cesarman G.M., Jacovina A.T., McLaughlin M.A., Lev E.A., Hajjar K.A. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999, 340(13):994-1004.
59. Stein E., McMahon B., Kwaan H., Altman J.K., Frankfurt O., Tallman M.S. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009, 22(1):153-163.
60. O'Connell P.A., Madureira P.A., Berman J.N., Liwski R.S., Waisman D.M. Regulation of S100A10 by the PML-RAR-α oncoprotein. Blood 2011, 117(15):4095-4105.
61. Bailey K., Bettelheim F.R., Lorand L., Middlebrook W.R. Action of thrombin in the clotting of fibrinogen. Nature 1951, 167(4241):233-234.
62. Bailey K., Bettelheim F.R. The clotting of fibrinogen. I. The liberation of peptide material. Biochim Biophys Acta 1955, 18(4):495-503.
63. Latallo Z.S., Fletcher A.P., Alkjaersig N., Sherry S. Inhibition of fibrin polymerization by fibrinogen proteolysis products. Am J Physiol 1962, 202:681-686.
64. Khalafallah A., Jarvis C., Morse M., Albarzan A.M., Stewart P., Bates G., et al. Evaluation of the innovance d-dimer assay for the diagnosis of disseminated intravascular coagulopathy in different clinical settings. Clin Appl Thromb Hemost 2014, 20(1):91-97.
65. van der Hulle T., Tan M., den Exter P.L., Mol G.C., Iglesias del Sol A., van de Ree M.A., et al. Selective D-dimer testing for the diagnosis of acute deep vein thrombosis: a validation study. J Thromb Haemost 2013, 11(12):2184-2186.
66. van der Hulle T., den Exter P.L., Erkens P.G., van Es J., Mos I.C., ten Cate H., et al. Variable D-dimer thresholds for diagnosis of clinically suspected acute pulmonary embolism. J Thromb Haemost 2013, 11(11):1986-1992.
67. Gomes M., Khorana A.A. Risk assessment for thrombosis in cancer. Semin Thromb Hemost 2014, 40(3):319-324.
68. Jennewein C., Tran N., Paulus P., Ellinghaus P., Eble J.A., Zacharowski K. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 2011, 17(5-6):568-573.
69. Senior R.M., Skogen W.F., Griffin G.L., Wilner G.D. Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B. J Clin Investig. 1986, 77(3):1014-1019.
70. Richardson D.L., Pepper D.S., Kay A.B. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol 1976, 32(4):507-513.
71. Lalla R.V., Tanzer M.L., Kreutzer D.L. Identification of a region of the fibrin molecule involved in upregulation of interleukin-8 expression from human oral squamous cell carcinoma cells. Arch Oral Biol 2003, 48(4):263-271.
72. Roesner J.P., Petzelbauer P., Koch A., Tran N., Iber T., Vagts D.A., et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med 2009, 37(2):598-605.
73. Gröger M., Pasteiner W., Ignatyev G., Matt U., Knapp S., Atrasheuskaya A., et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS ONE 2009, 4(4):e5391.
74. Pandi L., Kollman J.M., Lopez-Lira F., Burrows J.M., Riley M., Doolittle R.F. Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms. Biochemistry 2009, 48(30):7201-7208.
75. Mischke R., Wolling H., Nolte I. Detection of anticoagulant activities of isolated canine fibrinogen degradation products X, Y, D and E using resonance thrombography. Blood Coagul Fibrinolysis 2004, 15(1):81-88.
76. Mischke R., Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis 2000, 30(3):123-130.
77. Ittyerah T.R., Weidner N., Wochner R.D., Sherman L.A. Effect of fibrin degradation products and thrombin on fibrinogen synthesis. Br J Haematol 1979, 43(4):661-668.
78. Omar M.N., Mann K.G. Inactivation of factor Va by plasmin. J Biol Chem 1987, 262:9750-9755.
79. McKee P.A., Anderson J.C., Switzer M.E. Molecular structural studies of human factor VIII. Ann N Y Acad Sci 1975, 240:8-33.
80. Esmon C.T. The regulation of natural anticoagulant pathways. Science 1987, 235:1348-1352.
81. Stricker R.B., Wong D., Shiu D.T., Reyes P.T., Shuman M.A. Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. Blood 1986, 68:275-280.
82. Adelman B., Michelson A.D., Greenberg J., Handin R.I. Proteolysis of platelet glycoprotein by plasmin is facilitated by plasmin lysine-binding regions. Blood 1986, 68:1280-1284.
83. Gimple L.W., Gold H.K., Leinbach R.C., Coller B.S, Werner W., Yasuda T., et al. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant issue type plasminogen activator. Circulation 1989, 80:581-588.
84. Coller B.S. Platelets and thrombolytic therapy. N Engl J Med 1990, 322:33-42.
85. Esmon C.T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989, 264:4743-4746.
86. Grinnell B.W., Berg D.T. Surface thrombomodulin modulates thrombin receptor responses on vascular smooth muscle cells. Am J Physiol 1996, 270:H603-H609.
87. Lafay M., Laguna R., Le Bonniec B.F., Lasne D., Aiach M., Rendu F. Thrombomodulin modulates the mitogenic response to thrombin of human umbilical vein endothelial cells. Thromb Haemost 1998, 79:848-852.
88. Bajzar L., Manuel R., Nesheim M. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem 1995, 270:14477-14484.
89. de Munk G.A.W., Groeneveld E., Rijken D.C. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 1991, 88:1680-1684.
90. Molinari A., Giorgetti C., Lansen J., Vaghi F., Orsini G., Faioni E.M., et al. Thrombomodulin is a cofactor for thrombin degradation of recombinant single-chain urokinase plasminogen activator in vitro and in a perfused rabbit heart model. Thromb Haemost 1992, 67:226-232.
91. Preissner K.T., May A.E., Wohn K.D., Germer M., Kanse S.M. Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemost 1997, 78:88-95.
92. Esmon C.T., Scriver C.R., Beaudet A.L., Sly W.S., Valle D. Anticoagulant protein C/thrombomodulin pathway. The Metabolic and Molecular Bases of Inherited Disease 2001, vol. 8th:4327-4343. McGraw-Hill, Montreal.
93. de Moerloose P., Neerman-Arbez M. Treatment of congenital fibrinogen disorders. Expert Opin Biol Ther 2008, 8(7):979-992.
94. Matsuda M., Sugo T., Yoshida N., Terukina S., Yamazumi K., Niwa K., et al. Structure and function of fibrinogen: insights from dysfibrinogens. Thromb Haemost 1999, 82(2):283-290.
95. Côté H.C., Lord S.T., Pratt K.P. gamma-Chain dysfibrinogenemias: molecular structure-function relationships of naturally occurring mutations in the gamma chain of human fibrinogen. Blood 1998, 92(7):2195-2212.
96. Lijnen H.R., Soria J., Soria C., Collen D., Caen J.P. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984, 51(1):108-109.
97. Lak M., Keihani M., Elahi F., Peyvandi F., Mannucci P.M. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999, 107(1):204-206.
98. Dupuy E., Habib A., Lebret M., Yang R., Levy-Toledano S., Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1alpha. J Thromb Haemost 2003, 1(5):1096-1102.
99. Manco-Johnson M.J., Dimichele D., Castaman G., Fremann S., Knaub S., Kalina U., et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009, 7(12):2064-2069.
100. Bornikova L., Peyvandi F., Allen G., Bernstein J., Manco-Johnson M.J. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011, 9(9):1687-1704.
101. Chapin J., DeSancho M. Pulmonary embolism in a patient with congenital afibrinogenemia. Haemophilia 2013, 19(6):e380-e382.
102. Hunt B.J. Bleeding and coagulopathies in critical care. N Engl J Med 2014, 370(22):2153.
103. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. N Engl J Med 2011, 365(2):147-156.
104. Malyszko J., Malyszko J.S., Mysliwiec M. Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome. Blood Coagul Fibrinolysis 2002, 13(7):615-621.
105. Cucuianu M., Knauer O., Roman S. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states. Thromb Haemost 1991, 66(5):586-591.
106. Sallah S., Gagnon G.A. Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel. Cancer Investig 2000, 18(3):191-196.
107. Meikle A.W., Graybill J.R. Fibrinolysis and hemorrhage in a fatal case of heat stroke. N Engl J Med 1967, 276(16):911-913.
108. Bouchama A., Bridey F., Hammami M.M., Lacombe C., al-Shail E., al-Ohali Y., et al. Activation of coagulation and fibrinolysis in heatstroke. Thromb Haemost 1996, 76(6):909-915.
109. Hess J.R., Brohi K., Dutton R.P., Hauser C.J., Holcomb J.B., Kluger Y., et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008, 65(4):748-754.
110. Edmunds L.H. Managing fibrinolysis without aprotinin. Ann Thorac Surg 2010, 89(1):324-331.
111. Krone K.A., Allen K.L., McCrae K.R. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12(1):53-57.
112. Arteel G.E. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol 2008, 23(Suppl. 1):S54-S59.
113. Mazur P., Sokołowski G., Hubalewska-Dydejczyk A., Płaczkiewicz-Jankowska E., Undas A. Prothrombotic alterations in plasma fibrin clot properties in thyroid disorders and their post-treatment modifications. Thromb Res 2014, 134(2):510-517.
114. van Marion A.M., Auwerda J.J., Minnema M.C., van Oosterom R., Adelmeijer J., de Groot P.G., et al. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. Thromb Haemost 2005, 94(6):1341-1343.
115. Deng A., Gocke C.D., Hess J., Heyman M., Paltiel M., Gaspari A. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006, 142(11):1466-1469.
116. Pizzo S.V., Murray J.C., Gonias S.L. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med 1986, 110(6):517-519.
117. Tefs K., Gueorguieva M., Klammt J., Allen C.M., Aktas D., Anlar F.Y., et al. Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood 2006, 108(9):3021-3026.
118. Schuster V., Hügle B., Tefs K. Plasminogen deficiency. J Thromb Haemost 2007, 5(12):2315-2322.
119. Mehta R., Shapiro A.D. Plasminogen deficiency. Haemophilia 2008, 14(6):1261-1268.
120. Miyauchi Y., Mii Y., Aoki M., Tamai S., Takahashi Y., Yoshioka A. Operative treatment of intramedullary hematoma associated with congenital deficiency of alpha 2-plasmin inhibitor: a report of three cases. J Bone Joint Surg Am 1996, 78(9):1409-1414.
121. Carpenter S.L., Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia 2008, 14(6):1250-1254.
122. Iwaki T., Urano T., Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012, 157(3):291-298.
123. Iwaki T., Nagahashi K., Kobayashi T., Umemura K., Terao T., Kanayama N. The first report of uncontrollable subchorionic and retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. Thromb Res 2012, 129(4):e161-e163.
124. Mehta R., Shapiro A.D. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008, 14(6):1255-1260.
125. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R., et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994, 368(6470):419-424.
126. Karamanavi E., Angelopoulou K., Lavrentiadou S., Tsingotjidou A., Abas Z., Taitzoglou I., et al. Urokinase-type plasminogen activator deficiency promotes neoplasmatogenesis in the colon of mice. Transl Oncol 2014, 7(2). [174-187.e175].
127. Hugenholtz G.C., Meijers J.C., Adelmeijer J., Porte R.J., Lisman T. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. Thromb Haemost 2013, 109(5):948-955.
128. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Shen C., Newcomer L.M., et al. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992, 85(5):1822-1827.
129. Crowther M.A., Roberts J., Roberts R., Johnston M., Stevens P., Skingley P., et al. Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001, 85(3):390-394.
130. Folsom A.R., Cushman M., Heckbert S.R., Rosamond W.D., Aleksic N. Prospective study of fibrinolytic markers and venous thromboembolism. J Clin Epidemiol 2003, 56(6):598-603.
131. van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95(9):2855-2859.
132. Lisman T., de Groot P.G., Meijers J.C., Rosendaal F.R. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005, 105(3):1102-1105.
133. Meltzer M.E., Lisman T., Doggen C.J., de Groot P.G., Rosendaal F.R. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008, 5(5):e97.
134. Hoekstra J., Guimarães A.H., Leebeek F.W., Darwish Murad S., Malfliet J.J., Plessier A., et al. Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 2010, 115(2):388-395.
135. Meltzer M.E., Doggen C.J., de Groot P.G., Rosendaal F.R., Lisman T. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 2009, 145(1):121-127.
136. Meltzer M.E., Lisman T., de Groot P.G., Meijers J.C., le Cessie S., Doggen C.J., et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010, 116(1):113-121.
137. Meltzer M.E., Doggen C.J., de Groot P.G., Meijers J.C., Rosendaal F.R., Lisman T. Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men. Haematologica 2009, 94(6):811-818.
138. De Wee E.M., Klaij K., Eikenboom H.C., Van Der Bom J.G., Fijnvandraat K., Laros-Van Gorkom B.A., et al. Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease. Haemophilia 2012, 18(3):444-451.
139. Rijken D.C., Kock E.L., Guimarães A.H., Talens S., Darwish Murad S., Janssen H.L., et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012, 10(10):2116-2122.
140. Sivula M., Pettilä V., Niemi T.T., Varpula M., Kuitunen A.H. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2009, 20(6):419-426.
141. Ogawa S., Szlam F., Chen E.P., Nishimura T., Kim H., Roback J.D., et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2012, 52(1):14-22.
142. Brazzel C. Thromboelastography-guided transfusion. Therapy in the trauma patient. AANA J 2013, 81(2):127-132.
143. Schöchl H., Cotton B., Inaba K., Nienaber U., Fischer H., Voelckel W., et al. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care 2011, 15(6):R265.
144. Huissoud C., Carrabin N., Benchaib M., Fontaine O., Levrat A., Massignon D., et al. Coagulation assessment by rotation thrombelastometry in normal pregnancy. Thromb Haemost 2009, 101(4):755-761.
145. Schöchl H., Frietsch T., Pavelka M., Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009, 67(1):125-131.
146. Popa N.L., Wergedal J.E., Lau K.H., Mohan S., Rundle C.H. Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling. J Bone Miner Metab 2014, 32(2):124-135.
147. Dougherty K.M., Pearson J.M., Yang A.Y., Westrick R.J., Baker M.S., Ginsburg D. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 1999, 96(2):686-691.
148. Ling Q., Jacovina A.T., Deora A., Febbraio M., Simantov R., Silverstein R.L., et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004, 113(1):38-48.
149. Nikolopoulos G.K., Bagos P.G., Tsangaris I., Tsiara C.G., Kopterides P., Vaiopoulos A., et al. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis. Clin Chem Lab Med 2014, 52(7):937-950.
150. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Tsiara C.G., Kapsimali V., Travlou A., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis. Blood Coagul Fibrinolysis 2007, 18(5):497-504.
151. Tsantes A.E., Nikolopoulos G.K., Bagos P.G., Bonovas S., Kopterides P., Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 2008, 122(6):736-742.
152. Jannes J., Hamilton-Bruce M.A., Pilotto L., Smith B.J., Mullighan C.G., Bardy P.G., et al. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke 2004, 35(5):1090-1094.
153. Shi J., Zhi P., Chen J., Wu P., Tan S. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis. Thromb Res 2014, 134:610-616.
154. Verdú J., Marco P., Benlloch S., Lucas J. Association between the Thr325Ile and Ala147Thr polymorphisms of the TAFI gene and the risk of venous thromboembolic disease. Clin Appl Thromb Hemost 2008, 14(4):494-495.
155. Tàssies D., Roqué M., Monteagudo J., Martorell T., Sionis A., Arzamendi D., et al. Thrombin-activatable fibrinolysis inhibitor genetic polymorphisms as markers of the type of acute coronary syndrome. Thromb Res 2009, 124(5):614-618.
156. Bugge T.H., Flick M.J., Daugherty C.C., Degen J.L. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995, 9:794-807.
157. Ploplis V.A., Carmeliet P., Vazirzadeh S., Van Vlaenderen I., Moons L., Plow E.F., et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995, 92:2585-2593.
158. Lijnen H.R., Okada K., Matsuo O., Collen D., Dewerchin M. Alpha2-Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999, 93:2274-2281.
159. Carmeliet P., Kieckens L., Schoonjans L., Ream B., van Nuffelen A., Prendergast G., et al. Plasminogen activator inhibitor-1 gene-deficient mice: I. Generation by homologous recombination and characterization. J Clin Invest 1993, 92:2746-2755.
160. Nagashima M., Yin Z.F., Zhao L., White K., Zhu Y., Lasky N., et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002, 109(101):110.
161. Wang X., Smith P.L., Hsu M.Y., Tamasi J.A., Bird E., Schumacher W.A. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007, 23:41-49.